Stryker (SYK) Stock Overview
Operates as a medical technology company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
SYK Community Fair Values
Create NarrativeSee what 94 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$323.52
FV
3.2% undervalued intrinsic discount6.00%
Revenue growth p.a.
340
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Stryker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$313.22 |
| 52 Week High | US$404.87 |
| 52 Week Low | US$281.00 |
| Beta | 0.81 |
| 1 Month Change | -8.77% |
| 3 Month Change | -15.16% |
| 1 Year Change | -20.64% |
| 3 Year Change | 9.45% |
| 5 Year Change | 21.80% |
| Change since IPO | 57,725.20% |
Recent News & Updates
Recent updates
Narrative Update • May 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside
Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.Analysis Article • May 04
Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...Narrative Update • Apr 21
SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside
Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.Narrative Update • Apr 06
SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside
The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.Narrative Update • Mar 22
SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside
Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.Narrative Update • Mar 07
SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside
The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.Narrative Update • Feb 20
SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside
Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.Analysis Article • Feb 09
Stryker's (NYSE:SYK) Earnings Seem To Be Promising
Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...Analysis Article • Feb 07
Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88
Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...Narrative Update • Feb 06
SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment
Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.Narrative Update • Jan 22
SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential
Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.Narrative Update • Jan 08
SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside
Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.Seeking Alpha • Jan 07
Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker
Summary Stryker offers above-average revenue growth, robust margin leverage, and a compelling valuation relative to med-tech peers despite sector-wide derating risks. Key growth drivers include Mako’s continued share gains in major joints, expansion into extremities, and under-tapped potential in ambulatory surgical centers. Management prioritizes M&A for capital allocation, targeting complementary technologies in robotics, cardiology, and urology, while organic growth opportunities like Smart Care add upside. With expected 9%+ revenue growth for FY’26 and EBITDA margins nearing 30%, SYK’s diversified base and disciplined strategy support an attractive risk/reward profile. Read the full article on Seeking AlphaNarrative Update • Dec 19
SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential
Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.Analysis Article • Dec 14
Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88
Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...Analysis Article • Sep 08
Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Aug 08
Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality
NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...Analysis Article • Jul 09
Estimating The Intrinsic Value Of Stryker Corporation (NYSE:SYK)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stryker fair value estimate is US$371 With US$390 share price...Analysis Article • Jun 16
With Stryker Corporation (NYSE:SYK) It Looks Like You'll Get What You Pay For
Stryker Corporation's ( NYSE:SYK ) price-to-earnings (or "P/E") ratio of 50.4x might make it look like a strong sell...Seeking Alpha • Jan 27
Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?
Summary Stryker Corporation is a high-quality, innovative medical device company with a strong history of revenue, earnings, and FCF growth, driven by R&D and M&A strategies. Shares are currently expensive with a PEG ratio around 3, but the company's consistent performance and market leadership justify a premium valuation. Stryker's strong company culture, impressive ROIC, and substantial insider ownership indicate a durable competitive advantage and a bright future. Despite current high valuations, long-term growth prospects remain solid, making it a hold for now, but a buy under $350. Read the full article on Seeking AlphaShareholder Returns
| SYK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 10.8% | 0.08% | -0.3% |
| 1Y | -20.6% | -24.4% | 24.1% |
Return vs Industry: SYK exceeded the US Medical Equipment industry which returned -24.4% over the past year.
Return vs Market: SYK underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| SYK volatility | |
|---|---|
| SYK Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SYK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SYK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 56,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products.
Stryker Corporation Fundamentals Summary
| SYK fundamental statistics | |
|---|---|
| Market cap | US$117.60b |
| Earnings (TTM) | US$3.34b |
| Revenue (TTM) | US$25.27b |
36.0x
P/E Ratio4.8x
P/S RatioIs SYK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYK income statement (TTM) | |
|---|---|
| Revenue | US$25.27b |
| Cost of Revenue | US$8.92b |
| Gross Profit | US$16.35b |
| Other Expenses | US$13.01b |
| Earnings | US$3.34b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.70 |
| Gross Margin | 64.70% |
| Net Profit Margin | 13.21% |
| Debt/Equity Ratio | 64.1% |
How did SYK perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield39%
Payout RatioDoes SYK pay a reliable dividends?
See SYK dividend history and benchmarks| Stryker dividend dates | |
|---|---|
| Ex Dividend Date | Jun 30 2026 |
| Dividend Pay Date | Jul 31 2026 |
| Days until Ex dividend | 42 days |
| Days until Dividend pay date | 73 days |
Does SYK pay a reliable dividends?
See SYK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/18 22:27 |
| End of Day Share Price | 2026/05/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stryker Corporation is covered by 58 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Matthew Miksic | Barclays |